Radiotherapy with a Radiolabeled Somatostatin Analogue, [<sup>111</sup>In‐DTPA‐<scp>d</scp>‐Phe<sup>1</sup>]‐Octreotide

Krenning, Eric P.; Kooij, P. P. M.; Bakker, Willem H.; Breeman, W. A. P.; Postema, P. T. E.; Kwekkeboom, Dik J.; Oei, H. Y.; Jong, Marion de; Visser, Theo J.; Reijs, Ambroos E.M.; Lamberts, Steven W. J.

doi:10.1111/j.1749-6632.1994.tb17300.x

Cited by 269 publications

(133 citation statements)

References 10 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5] Preliminary results of clinical trials with 111 In-DTPA-OC, a diagnostic radiopharmaceutical approved by the United States Food and Drug Administration, have demonstrated evidence of tumor response to treatment. 1,6 Reported responses include stable disease, but no significant tumor regressions or remissions. 90 Y-DOTA-Tyr 3 -octreotide ( 90 Y-DOTA-Y3-OC or 90 Y-DOTATOC or SMT487) is currently in clinical trials, with favorable results demonstrating significant tumor regressions.…”

mentioning

confidence: 99%

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

et al. 2001

View full text Add to dashboard Cite

; 92:628 -633). In the current study, the toxicity and dosimetry of 177 Lu-DOTA-Y3-TATE were determined in both normal and tumor-bearing rats. Doses of 177 Lu-DOTA-Y3-TATE ranging from 0 to 123 mCi/kg were administered to rats and complete blood counts (CBCs) and blood chemistries were analyzed out to 6 weeks. No overt signs of toxicity were observed with 177 Lu-DOTA-Y3-TATE (i.e., lethargy, weight loss, scruffy coat or diarrhea) at any of the dose levels. Blood chemistries and CBCs were normal except for the white blood cell counts, which showed a dose-dependent decrease. The maximum tolerated dose was not reached at 123 mCi/kg. The biodistribution of 177 Lu-DOTA-Y3-TATE was determined in CA20948 rat pancreatic tumor-bearing rats, and the data were used to estimate human absorbed doses to normal tissues. The dose-limiting organ was determined to be the pancreas, followed by the adrenal glands. The absorbed dose to the rat CA20948 tumor was estimated to be 336 rad/mCi (91 mGy/MBq). These data demonstrate that 177 Lu-DOTA-Y3-TATE is an effective targeted radiotherapy agent at levels that show minimal toxicity in this rat model.

show abstract

mentioning

confidence: 99%

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Krenning et al were the first to treat 21 patients with metastatic neuroendocrine tumours, where at least four doses of 6.6 GBq 111 In-pentetreotide were given (30). In a study by McCarthy et al (8), 35 patients entered a protocol that evaluated the effect of two doses (6.6 GBq) a month apart.…”

Section: Discussionmentioning

confidence: 99%

Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide

et al. 2003

View full text Add to dashboard Cite

Objective: To evaluate therapy with high doses of 111 Indium pentetreotide in a patient with bone metastases from a carcinoid of the pancreas. Case report: A 55-year-old male presented in November 1990 with stomach ache with dorsal irradiation. Ultrasonography and computed tomography (CT-) scans of the abdomen revealed a tumour of the tail of the pancreas and liver metastases. Histological examination revealed a neuroendocrine tumour. Surgery and polychemotherapy were initiated and after seven cycles a tumour regression of 30% was achieved. During follow-up multiple metastases were seen upon bone scintigraphy for which treatment with high doses Indium-111-octreotide was initiated. Materials and methods: The patient underwent eight cycles, with one cycle every 5 weeks. Each treatment consisted of an i.v. injection of 6 GBq Indium-111-pentetreotide. Comparing the results of the first and the last post-treatment scintigraphy, a regression of the number and intensity of uptake in the lesions was found. Bone scintigraphy showed a regression of the skeletal lesions as well, while X-ray, CT-scan and chromogranin-A levels showed stable disease. Conclusion: Results from the treatment of our patient indicate that the use of high dose radiolabelled somatostatin analogues could be of significant use, even in the case of bone metastases. To our knowledge, this is the first report describing therapeutic effects on bone metastases from a neuroendocrine tumour.

show abstract

“…This latter test takes advantage of the binding to tumor somatostatin receptors 2 and 5 and is 80-90% sensitive for both primary and metastatic NETS. 15 Management of the carcinoid syndrome is considered separate from that of metastatic disease, as some patients will develop metastatic NETs without biochemical functionality. The management of the symptoms of the carcinoid syndrome has vastly improved with the introduction of synthetic somatostatin analogs (USAoctreotide, Europe-lanreotide).…”

Section: Carcinoid Syndromementioning

confidence: 99%

“…6 All lesions are termed neuroendocrine tumors (heretofore referred to as ''NETs'') and are separated on the basis of histologic aggressiveness and location within the GI tract. Grade 1 NETs are considered low-grade malignancies (<2 mitoses per high-powered field [HPF] ), grade 2 NETs are considered to be intermediate in behavior (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) mitoses/ HPF), and grade 3 are considered high grade (>20 mitoses/HPF). The original term ''carcinoid'' equates to NETs that are both grade 1 and 2 (well differentiated), whereas grade 3 NETs are mostly small cell carcinomas with a minority component being large cell type (poorly differentiated).…”

mentioning

confidence: 99%

Carcinoid and Other Neuroendocrine Tumors of the Colon and Rectum

Eggenberger¹

2011

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are found throughout the intestinal tract and arise from the Kulchitsky cells located in the crypts of Lieberkühn. They are classified by site of origin and by degree of differentiation, with well-differentiated lesions representing those tumors formerly referred to as carcinoid tumors. The focus of this review is NETs of the appendix, colon, and rectum. The clinical presentation of these tumors is dependent on the primary site and many are discovered incidentally, either during screening or during the investigation of nonspecific abdominal complaints. Treatment is primarily via surgical removal as the response to chemotherapy has been traditionally poor. A noted exception to this has been with treatment of the carcinoid syndrome, which occurs almost exclusively in patients with liver metastases and is due to the release of bioactive peptides and amines directly into the systemic circulation. The use of somatostatin congeners to block the release of these substances has greatly ameliorated the devastating symptoms of this condition. Postresection follow-up is advocated, but specific recommendations are lacking an evidentiary basis. NETS, particularly those of the small bowel, colon, and appendix, are seen in association with other synchronous or metachronous malignancies, often of the gastrointestinal tract. However, the utility of subsequent screening and surveillance is unproven.

show abstract

Radiotherapy with a Radiolabeled Somatostatin Analogue, [¹¹¹In‐DTPA‐d‐Phe¹]‐Octreotide

Cited by 269 publications

References 10 publications

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide

Carcinoid and Other Neuroendocrine Tumors of the Colon and Rectum

Contact Info

Product

Resources

About

Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide

Cited by 269 publications

References 10 publications

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide

Carcinoid and Other Neuroendocrine Tumors of the Colon and Rectum

Contact Info

Product

Resources

About

Radiotherapy with a Radiolabeled Somatostatin Analogue, [¹¹¹In‐DTPA‐d‐Phe¹]‐Octreotide